Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are prescribed to alleviate the pain and enhance mobility, but more-effective, well-tolerated alternatives are needed. Although there has been little recent innovation in this space, the pipeline for OA pain is active and diverse; several agents with novel mechanisms of action are in Phase 3 development (e.g., Gr\u00fcnenthal\u2019s resiniferatoxin, Kolon\u2019s TG-C). In this crowded and generic market, a deep understanding of patient characteristics, treatment patterns, and the competitive landscape is essential for the successful introduction of a novel analgesic.<\/p>\n
Questions answered<\/strong><\/p>\n Content highlights<\/strong><\/p>\n Geographies:<\/strong> United States, EU5<\/abbr>, Japan<\/p>\n Primary research: C<\/strong>ountry-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other Clarivate research<\/p>\n Epidemiology: <\/strong>Number of osteoarthritic pain patients by country, including diagnosed and drug-treated osteoarthritic pain patients<\/p>\n Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key OA<\/abbr> pain therapies through 2034, segmented by brands \/ generics<\/p>\n Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n Product description<\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n